An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good.
Britain’s biggest drugmaker said on Thursday the research was being accelerated with funding from an international consortium, reflecting mounting concern over the worst-ever outbreak of the disease in West Africa that has killed more than 1,500 people.
The candidate vaccine, which is being co-developed with the U.S. National Institutes of Health (NIH), is expected to be given to healthy volunteers in Britain and the United States from around mid-September, with the program then being extended to volunteers in Gambia and Mali.
(Reporting by Ben Hirschler, Editing by Paul Sandle)
More from Reuters:
- Obama’s Friend Pras Michel Heads To North Korea For Wrestling Match
- Online Fashion Retailer Zalando Gets Makeover As Eyes Listing
- Chipmaker CSR Rejects Microchip Approach, Shares Soar
- Israelis Search Jerusalem Forest For Missing American Student
- OncoMed Says FDA Lifts Partial Hold On Cancer Drug Trials
Business Insider Emails & Alerts
Site highlights each day to your inbox.